25 January 2023 in Intensive and Critical Care Nursing
LKLioudmila V. Karnatovskaia
Lioudmila V. Karnatovskaia
3 July 2022 in Diseases of the Esophagus
Topical steroids are commonly used in treatment of eosinophilic esophagitis (EoE), but currently there is lack of data to clarify most effective regimen. We aimed to study the achievement of histologic remission using the same dose of budesonide in two different delivery formulations. Patients with established EoE treated with pharmacy compounded budesonide capsule or budesonide Rincinol gel (both 3 mg twice daily) were studied retrospectively. Those with pre-treatment and post-treatment histologic assessment were included with main endpoint being histologic remission. 103 patients (62 gel, 41 capsule) were included, with higher rate of histologic remission with gel (84 vs. 59%, P=0.004). A subset of patients in both groups had lack of steroid response (<50% drop in eosinophils) (15% for gel, 32% for capsule). Formulation/delivery vehicle of steroid treatments to esophageal mucosa in EoE appears important for treatment efficacy, with budesonide gel having higher likelihood of histologic remission compared to budesonide capsules in our population. A truly steroid refractory group appears likely in our population. Larger, prospective studies may help clarify best regimen of topical steroids in EoE and may work to identify patients likely to benefit from alternative therapies.
5 September 2021 in European Respiratory Journal
Introduction: Oral appliance therapy (OAT) is a treatment option for patients with mild-moderate obstructive sleep apnea (OSA) intolerant to positive pressure therapy. Current guidelines recommend objective follow-up testing for OAT with polysomnography or home sleep studies. (Ramar, K et al. J Clin Sleep Med. 2015) Aim: Given the lack of high-quality evidence, we sought to describe the current practices regarding follow-up testing and changes in treatment strategies due to test results in our institution. Methods: We performed a chart review of OSA patients evaluated for OAT in 2019. We obtained patient information, follow-up testing strategy, and outcomes regarding further titration of the OAT or transition to other treatment strategies. Results: We screened 226 patients and included 182 patients in the study. The main reasons for exclusion were lack of OSA diagnosis (AHI <5), intolerance to OAT, and transfers. During the study period, 65 patients did not receive planned follow-up testing after OAT initiation, and 15 patients had no plans for follow-up testing determined by their Sleep medicine clinician. 103 patients received follow-up testing, with WatchPAT (67%, 70 tests) and oximetry (28%, 30 tests) being the most common strategies. Follow-up testing resulted in further titration of the OA or change in treatment strategy for 37 patients (36%), including 11 patients abandoning OAT. Conclusion: Most patients treated with OAT received follow-up testing, most frequently with home sleep studies. Over one-third of patients receiving follow-up testing ultimately receive further titration of OAT or transition to a different treatment strategy. Objective testing assessment of OAT response is often warranted.